<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01053234</url>
  </required_header>
  <id_info>
    <org_study_id>RRS 2006-1032</org_study_id>
    <nct_id>NCT01053234</nct_id>
  </id_info>
  <brief_title>Different Insulin Regimens and Postprandial Coagulation Activation</brief_title>
  <official_title>Effects of Standardised Meals on Postprandial Coagulation Activation in Patients With Type 2 Diabetes Treated With Two Different Insulin Regimens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital of South West Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ribe County Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital of South West Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study in patients with type 2 diabetes was to investigate the acute
      effect of postprandial blood glucose levels modified by two different insulin treatment
      regimens on coagulation activation, inflammation and endothelial cell function. The
      investigators hypothesized that the rapid-acting insulin analogue aspart has a beneficial
      postprandial effect on coagulation, endothelial dysfunction and inflammation compared with
      the intermediate-acting insulin NPH due to its ability to lower postprandial glycaemia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prothrombin fragment 1+2</measure>
    <time_frame>7.40; 9.30; 11.30; 13.30; 15.30</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein</measure>
    <time_frame>7.40; 9.30; 11.30; 13.30; 15.30</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Cardiovascular Risk</condition>
  <condition>Hemostasis</condition>
  <condition>Inflammation</condition>
  <condition>Endothelial Function</condition>
  <arm_group>
    <arm_group_label>Insulin aspart</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>NPH insulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Standardised meals</intervention_name>
    <arm_group_label>Insulin aspart</arm_group_label>
    <arm_group_label>NPH insulin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 30-75 years

          -  BMI &gt; 25 kg/m2

          -  type 2 diabetes for more than 4 years

          -  pharmacological anti-diabetic treatment with insulin NPH at bedtime or insulin aspart
             at meals for more than 24 months

          -  metformin with stable dose &gt;1000 mg/d for more than 12 weeks

          -  acetylsalicylic acid (75 mg/d) for more than 2 weeks

          -  no other anti-diabetic treatment 3 month previously

          -  HbA1c&lt;8.5% at recruitment.

        Exclusion Criteria:

          -  creatinine &gt; 120 Âµmol/l

          -  ALAT /ASAT &gt; 2.5 x upper reference limit

          -  use of anticoagulants within 1 month previously

          -  any changes in dose of statins within 1 month previously

          -  night work

          -  present or planned pregnancy

          -  mental sickness or alcohol abuse

          -  clinically relevant major organ or systemic illness

          -  uncontrolled hypertension &gt;180/110 mmHg

          -  steroid treatment

          -  known or suspected allergy to trial medications.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeppe Gram, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Medicine, Hospital of South West Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital of South West Denmark</name>
      <address>
        <city>Esbjerg</city>
        <zip>6700</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2010</study_first_submitted>
  <study_first_submitted_qc>January 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2010</study_first_posted>
  <last_update_submitted>January 20, 2010</last_update_submitted>
  <last_update_submitted_qc>January 20, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2010</last_update_posted>
  <responsible_party>
    <name_title>Chief physician, Ph.D Jeppe Gram</name_title>
    <organization>Department of Medicine, Hospital of South West Denmark</organization>
  </responsible_party>
  <keyword>Hyperglycaemia</keyword>
  <keyword>Postprandial</keyword>
  <keyword>Type 2 diabetes</keyword>
  <keyword>Cardiovascular risk markers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

